Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3902642 | 0.85 | MAOA (0.50) | MAOAMAOBDAOSLC6A4CYP3A4 | |
| SCHEMBL16293753 | 0.82 | HTR6 (0.69) | MAOAMAOBHTR2CHTR6SLC6A4 | |
| SCHEMBL3892154 | 0.81 | TDP1 (0.61) | TDP1MAOAMAOBSLC6A4CYP3A4 | |
| Bromide SCHEMBL16295457 | 0.81 | HTR6 (0.67) | MAOAMAOBHTR2CHTR6SLC6A4 | |
| SCHEMBL1710559 | 0.79 | HTR6 (0.56) | MAOAMAOBHTR2CHTR6SLC6A4 | |
| SCHEMBL7234763 | 0.79 | HDAC3 (0.59) | TDP1MAOAMAOB | |
| SCHEMBL7845531 | 0.79 | TDP1 (0.50) | TDP1CYP4F2CYP4A11HTR2CHTR6 | |
| SCHEMBL30990576 | 0.78 | TP53 (0.54) | MAOAMAOBHTR2CHTR6DAO | |
| SCHEMBL13459307 | 0.78 | LOXL2 (0.54) | MAOAMAOBHTR2CHTR6DAO | |
| SCHEMBL9454156 | 0.78 | MAOA (0.50) | MAOAMAOBHTR2CHTR6DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264660-A1 | PROCESS FOR ALKYL ARYL SULFIDE DERIVATIVES AND NEW SULFIDE COMPOUNDS | Kang, Heonjoong (KR) | 2009-10-22 | — | — | US | claimed |
| EP-1812386-A1 | PROCESS FOR ALKYL ARYL SULFIDE DERIVATIVES AND NEW SULFIDE COMPOUNDS | Kang, Heonjoong (KR) | 2007-08-01 | — | — | EP | claimed |
| WO-2006043797-A1 | PROCESS FOR ALKYL ARYL SULFIDE DERIVATIVES AND NEW SULFIDE COMPOUNDS | KANG HEONJOONG (KR) | 2006-04-27 | — | — | WO | claimed |
| US-20220389031-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-12-08 | — | — | US | disclosed |
| US-20220389031-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-12-08 | — | — | US | disclosed |
| US-20220289766-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-09-15 | — | — | US | disclosed |
| EP-4013762-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2022-06-22 | — | — | EP | disclosed |
| EP-4013761-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2022-06-22 | — | — | EP | disclosed |
| CN-114555609-A | Macrocyclic sulfonamide derivatives useful as NLRP3 inhibitors | 英夫拉索姆有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114401971-A | Macrocyclic sulfonylurea derivatives as NLRP3 inhibitors | 英夫拉索姆有限公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2021032588-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032588-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032591-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032591-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-02-25 | — | — | WO | disclosed |
| US-20090264660-A1 | PROCESS FOR ALKYL ARYL SULFIDE DERIVATIVES AND NEW SULFIDE COMPOUNDS | Kang, Heonjoong (KR) | 2009-10-22 | — | — | US | disclosed |
| US-20090264660-A1 | PROCESS FOR ALKYL ARYL SULFIDE DERIVATIVES AND NEW SULFIDE COMPOUNDS | Kang, Heonjoong (KR) | 2009-10-22 | — | — | US | disclosed |
| US-20090264660-A1 | PROCESS FOR ALKYL ARYL SULFIDE DERIVATIVES AND NEW SULFIDE COMPOUNDS | Kang, Heonjoong (KR) | 2009-10-22 | — | — | US | disclosed |
| EP-1812386-A1 | PROCESS FOR ALKYL ARYL SULFIDE DERIVATIVES AND NEW SULFIDE COMPOUNDS | Kang, Heonjoong (KR) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006043797-A1 | PROCESS FOR ALKYL ARYL SULFIDE DERIVATIVES AND NEW SULFIDE COMPOUNDS | KANG HEONJOONG (KR) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264660-A1 | PROCESS FOR ALKYL ARYL SULFIDE DERIVATIVES AND NEW SULFIDE COMPOUNDS | TST, ARSA, STS | TDP1 4840/4885MAOA 732/4885MAOB 492/4885 |
| US-20220289766-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | TDP1 1302/4885MAOA 4529/4885MAOB 4346/4885 |
| US-20220389031-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | TDP1 1152/4885MAOA 4145/4885MAOB 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.